Survival benefit of transcatheter arterial chemoembolization in patients with hepatocellular carcinoma larger than 10 cm in diameter
Open Access
- 13 December 2005
- journal article
- research article
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 23 (1), 129-135
- https://doi.org/10.1111/j.1365-2036.2006.02704.x
Abstract
Summary Background The safety and survival benefit of transcatheter arterial chemoembolization for patients with huge hepatocellular carcinoma is uncertain. Aim To evaluate the role of embolization in unresectable hepatocellular carcinomas larger than 10 cm. Methods Twenty‐six consecutive patients who had an unresectable hepatocellular carcinoma larger than 10 cm and refused aggressive treatment, were enrolled as the control group. Another 31 patients matching with the control cases and undergoing embolization for huge unresectable hepatocellular carcinoma served as the embolization group. Survival between the two groups was compared. Results Two patients (7%) died from embolization‐related complications. Patients in embolization group had longer survival than those in control group (median survival: 9.13 vs. 2.1 months). The 1‐, 3‐ and 5‐year survival rates in embolization group were 42%, 13% and 7% respectively. The 1‐ and 3‐year survival rates for patients in control group were 8% and 0% respectively. In multivariate analysis, embolization and prothrombin ratio ≤1.2 were two independent factors associated with a better survival. Conclusions Embolization‐related mortality is low for huge hepatocellular carcinoma, and the technique provides survival benefit in patients with unresectable hepatocellular carcinomas larger than 10 cm in diameter.Keywords
This publication has 22 references indexed in Scilit:
- Comparison of recurrence after hepatic resection in patients with hepatitis B vs. hepatitis C‐related small hepatocellular carcinoma in hepatitis B virus endemic areaLiver International, 2005
- The role of transcatheter arterial embolization for patients with unresectable hepatocellular carcinoma: a nationwide, multicentre study evaluated by cancer stageAlimentary Pharmacology & Therapeutics, 2005
- Incidence and risk factors for acute renal failure in patients with hepatocellular carcinoma undergoing transarterial chemoembolization: a prospective studyLiver International, 2004
- Acute renal failure after transarterial chemoembolization for hepatocellular carcinoma: a retrospective study of the incidence, risk factors, clinical course and long‐term outcomeAlimentary Pharmacology & Therapeutics, 2004
- Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survivalHepatology, 2003
- Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trialThe Lancet, 2002
- Supportive treatment, resection and transcatheter arterial chemoembolization in resectable hepatocellular carcinomaEuropean Journal of Gastroenterology & Hepatology, 1999
- Surgical treatment and outcome in patients with a hepatocellular carcinoma greater than 10 cm in diameterBritish Journal of Surgery, 1998
- Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization: a multicenter randomized trialJournal of Hepatology, 1998
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958